Stocks · News reference
Centene beat Q2 earnings and revenue estimates, raised its 2026 outlook, improved medical cost trends, and reported lower Medicaid membership.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
The program, which will initially be available to more than 160,000 qualifying providers nationwide for select outpatient services, is designed to streamline the prior authorization review process while maintaining
Oscar Health (OSCR) has surged 130% year-to-date driven by ACA marketplace expansion and plans to enter 150+ metro areas by 2027. However, the stock trades at a premium 4.94 price-to-book ratio versus the industry average of 2.64, and long-term profitability depends on disciplined underwriting and cost management rather than favorable policy conditions alone. Concentration risk from ACA exposure and potential subsidy policy changes pose headwinds.
Molina Healthcare is expected to report a significant year-over-year earnings decline of 60.9% to $0.72 per share for Q3 2026, with revenues down 4.8% to $10.93 billion. The stock carries a Zacks Rank #4 (Sell) with a negative Earnings ESP of -3.30%, making it unlikely to beat consensus estimates. While the company has beaten estimates in 2 of the last 4 quarters, current analyst sentiment has turned bearish with recent estimate revisions.
Humana affirms its guidance of at least $9.00 in adjusted earnings per common share ("Adjusted EPS"), for the year ending December 31, 2026 ("FY 2026"). This guidance is consistent with the guidance